Phase 2Active, not recruiting
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
- Sponsor
- M.D. Anderson Cancer Center (Academic or other)
- Enrolment
- 25 enrolled
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin; Doxorubicin Hydrochloride; Pembrolizumab; Dacarbazine
- Ages
- adults, older adults
- Registry
- NCT05922904
From the registry
To learn about the effects of brentuximab vedotin and pembrolizumab in combination with doxorubicin and dacarbazine when given to patients who have Stage II cHL with bulky mediastinal disease or advanced cHL (Stage III or IV) and who have not received treatment for the disease.
Primary outcomes
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0